行情

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

0.4905
-0.0095
-1.90%
盘前: 0.4951 +0.0046 +0.94% 08:25 04/01 EDT
开盘
0.5465
昨收
0.5000
最高
0.5499
最低
0.4700
成交量
113.53万
成交额
--
52周最高
3.440
52周最低
0.4500
市值
2,158.45万
市盈率(TTM)
-0.1068
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SEEL价格均价为6.00,最高价位8.00,最低价为4.000。

EPS

SEEL 新闻

更多
  • 沙特抵制特朗普调解石油价格战的尝试 供应量达到创纪录水平
  • 新浪财经 · 35分钟前
  • 疫情冲击下 美零售巨头梅西百货临时解雇13万人
  • 观察者网 · 47分钟前
  • 从-9%到-40%,一切预测都是瞎猜?
  • 新浪财经综合 · 57分钟前
  • 别管美国经济是否会萎缩34%了,黄金月线出现了危险一幕
  • 新浪财经综合 · 58分钟前

所属板块

制药
-0.13%
制药与医学研究
-0.25%

热门股票

代码
价格
涨跌幅

SEEL 简况

Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).
展开

微牛提供Seelos Therapeutics Inc(NASDAQ-SEEL)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SEEL股票新闻,以帮助您做出投资决策。